[go: up one dir, main page]

MX2024011081A - Anticuerpos multiespecíficos y usos de estos. - Google Patents

Anticuerpos multiespecíficos y usos de estos.

Info

Publication number
MX2024011081A
MX2024011081A MX2024011081A MX2024011081A MX2024011081A MX 2024011081 A MX2024011081 A MX 2024011081A MX 2024011081 A MX2024011081 A MX 2024011081A MX 2024011081 A MX2024011081 A MX 2024011081A MX 2024011081 A MX2024011081 A MX 2024011081A
Authority
MX
Mexico
Prior art keywords
antigen
nucleic acids
multispecific antibodies
binding
vectors
Prior art date
Application number
MX2024011081A
Other languages
English (en)
Inventor
Sanjaya Singh
Danlin Yang
Bidisha Dasgupta
Rupesh Nanjunda
Adam Zwolak
Wilson Edwards
Rosario Brian Del
Thomas Kelly
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2024011081A publication Critical patent/MX2024011081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan anticuerpos multiespecíficos o fragmentos de unión al antígeno de estos que comprenden al menos una primera región de unión al antígeno capaz de unirse específicamente al piroglutamato amiloide-? y una segunda región de unión al antígeno capaz de unirse específicamente al receptor de transferrina (TfR). También se proporcionan métodos para tratar o detectar un trastorno neurológico y/o suministrar un agente terapéutico o de diagnóstico a través de la barrera hematoencefálica. También se describen ácidos nucleicos que codifican los anticuerpos, vectores que comprenden los ácidos nucleicos, células huésped recombinantes que comprenden los ácidos nucleicos y/o vectores, y métodos para producir los anticuerpos multiespecíficos o fragmentos de unión al antígeno de estos.
MX2024011081A 2022-03-11 2024-09-10 Anticuerpos multiespecíficos y usos de estos. MX2024011081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263269204P 2022-03-11 2022-03-11
PCT/EP2023/056213 WO2023170291A1 (en) 2022-03-11 2023-03-10 Multispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2024011081A true MX2024011081A (es) 2024-12-06

Family

ID=85601724

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011081A MX2024011081A (es) 2022-03-11 2024-09-10 Anticuerpos multiespecíficos y usos de estos.

Country Status (11)

Country Link
US (1) US20250188181A1 (es)
EP (1) EP4490184A1 (es)
JP (1) JP2025509445A (es)
KR (1) KR20240159846A (es)
CN (1) CN119173531A (es)
AU (1) AU2023230027A1 (es)
CA (1) CA3254098A1 (es)
IL (1) IL315541A (es)
MX (1) MX2024011081A (es)
TW (1) TW202400636A (es)
WO (1) WO2023170291A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025172924A1 (en) * 2024-02-15 2025-08-21 Janssen Biotech, Inc. Anti-transferrin receptor compositions and methods thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5697151A (en) 1995-08-07 1997-12-16 General Electric Company Method for repairing partitions of a turbine diaphragm
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
BR112021019107A2 (pt) 2019-03-26 2021-11-30 Janssen Pharmaceutica Nv Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos
EP4132589A4 (en) 2020-04-08 2024-05-08 Aliada Therapeutics, Inc. COMPOSITIONS AND METHODS OF ADMINISTRATION AT THE BLOOD-BRAIN BARRIER

Also Published As

Publication number Publication date
CA3254098A1 (en) 2023-09-14
CN119173531A (zh) 2024-12-20
IL315541A (en) 2024-11-01
EP4490184A1 (en) 2025-01-15
TW202400636A (zh) 2024-01-01
JP2025509445A (ja) 2025-04-11
AU2023230027A1 (en) 2024-10-24
KR20240159846A (ko) 2024-11-06
US20250188181A1 (en) 2025-06-12
WO2023170291A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
Yu et al. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
PH12022552667A1 (en) Anti-cd98 antibodies and uses thereof
CN109790532B (zh) 抗lag-3抗体
BR112022020275A2 (pt) Composições e métodos para distribuição à barreira hematoencefálica
US10392444B2 (en) Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
Amann et al. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3
BR112022001902A2 (pt) Proteína biespecífica de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica e método para a produção da proteína biespecífica de ligação ao antígeno
RU2013141976A (ru) Новые модуляторы и способы их применения
RU2018139811A (ru) Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства
KR20240046533A (ko) 항-ccr8 항체 및 그것의 용도
JP2018521667A5 (es)
Wang et al. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma
MX2024011081A (es) Anticuerpos multiespecíficos y usos de estos.
JP2015516370A5 (es)
JP2016538297A5 (es)
US20240374745A1 (en) Biopharmaceutical prodrug platform based on protein conformational change
ES3036457T3 (en) A cd33-, cd16- and cd123-specific single chain triplebody
MX2024011083A (es) Anticuerpos multiespecíficos y usos de estos.
US20240398902A1 (en) Multivalent interferon particles compositions and methods of use
CN114929745B (zh) Clec12a抗体片段序列和方法
WO2022266341A1 (en) Targeted adam17 blocker compounds, anti-adam17 antibodies, methods of making, and methods of using
WO2021178960A2 (en) Compositions and methods for treatment of cancer
EP3766512A1 (en) Fc-modified il-12 for local cns delivery
US11369669B2 (en) Measles virus encoding a tumor antigen
MX2024011080A (es) Anticuerpos multiespecíficos y usos de estos.